Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
- PMID: 28943980
- PMCID: PMC5597808
- DOI: 10.18549/PharmPract.2017.03.979
Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
Abstract
Objective: 1) To evaluate the relationship between physician-pharmacist agreement about the off-label drug use and 2) and to identify the most common off-label medication category/indications and prescriber clinical disciplines in private settings in Baghdad area, Iraq.
Methods: This study evaluated 980 off-label use requests in the private clinical settings within Baghdad area, Iraq from October 2013 to September 2015. The efficacy, safety, and convenience of each drug request and its alternative options were evaluated according to the patient health and demographic characteristics and standard guidelines.
Results: Of the 980 physician off-label requests, only 22.7% were approved by the pharmacists. Rheumatology and Nephrology accounted for the highest ratio of off-label use requests for adults (30.3% and 26.3%). The pharmacist rejection ratio of off-label use was comparable between the two groups (p>0.05). Most of the issued requests were attributed either to unapproved indication or to combination of more than one drug (38% and 35.3%). A low acceptance rate was reported in the requests issued for treatment in different clinical lines to the authorized one (11.9%). The lowest rate of acceptance was reported in the requests that had very low evidence level (9.1%). The mostly prescribed medications were musculoskeletal agents (28.9%). Finally, 78.2% of the requests came from clinical branches for adults. Although the agreement rate for requests in adults was higher than that in pediatrics, the two rates were not significantly different.
Conclusion: Community pharmacists should effectively take responsibility for assessing off-label drug requests in Iraqi private settings. The quality of evidence does not represent the major factor influencing the approval rate of off-label drug use. The availability of safer and/or affordable alternatives and prescribing for a different patient age category highly impacted the pharmacists' approval rate.
Keywords: Attitude of Health Personnel; Interprofessional Relations; Iraq; Off-Label Use; Pharmacists; Physicians; Physicians’; Practice Patterns; Prospective Studies.
Conflict of interest statement
CONFLICT OF INTEREST Nothing to disclose.
Figures
Similar articles
-
The role of perceived impact on relationship quality in pharmacists' willingness to influence indication-based off-label prescribing decisions.Soc Sci Med. 2015 May;132:181-9. doi: 10.1016/j.socscimed.2015.03.028. Epub 2015 Mar 14. Soc Sci Med. 2015. PMID: 25818379 Clinical Trial.
-
Hospital pharmacists' perceived beliefs and responsibilities in indication-based off-label prescribing.Int J Clin Pharm. 2018 Feb;40(1):36-40. doi: 10.1007/s11096-017-0567-7. Epub 2017 Dec 4. Int J Clin Pharm. 2018. PMID: 29204800
-
Factors influencing the degree of physician-pharmacist collaboration within Iraqi public healthcare settings.Int J Pharm Pract. 2017 Dec;25(6):411-417. doi: 10.1111/ijpp.12339. Epub 2017 Feb 9. Int J Pharm Pract. 2017. PMID: 28181318
-
Trends in the off-label use of β-blockers in pediatric patients.Pediatr Int. 2019 Nov;61(11):1071-1080. doi: 10.1111/ped.14015. Epub 2019 Nov 12. Pediatr Int. 2019. PMID: 31571355 Review.
-
Pediatric Off-Label and Unlicensed Drug Use and Its Implications.Curr Clin Pharmacol. 2017;12(1):18-25. doi: 10.2174/1574884712666170317161935. Curr Clin Pharmacol. 2017. PMID: 28322168 Review.
Cited by
-
The role of medicines and therapeutics committees structure in supporting optimal antibacterial use in hospitals in Uganda: A mixed method study.PLoS One. 2024 Jan 19;19(1):e0289851. doi: 10.1371/journal.pone.0289851. eCollection 2024. PLoS One. 2024. PMID: 38241225 Free PMC article.
-
Polypharmacy in Pediatric Palliative Care: Exploring Discrepancies Between Physicians and Pharmacists.Children (Basel). 2025 Jan 24;12(2):124. doi: 10.3390/children12020124. Children (Basel). 2025. PMID: 40003226 Free PMC article.
-
A scientist engineer's contribution to therapeutic discovery and development.Exp Biol Med (Maywood). 2018 Oct;243(14):1125-1132. doi: 10.1177/1535370218813974. Epub 2018 Nov 20. Exp Biol Med (Maywood). 2018. PMID: 30458646 Free PMC article.
References
-
- Sivadas A, Aneesh SA, Koshy EM, Roshni PR, Sasidharan P. Development and implementation of pediatric formulary and drug therapy guide in a tertiary care hospital in India. Int J Pharm Pharm Sci. 2014;6(6):450–451.
LinkOut - more resources
Full Text Sources
Other Literature Sources